Program

Translations in Urologic Oncology

January 25th-26th, 2013

German Cancer Research Center (DKFZ), Communication Center, Heidelberg

www.uro-oncology2013.com
Dear colleagues,

Not long ago, the mantra was that science, like history, repeats itself. One of the major contributing facts to this phenomenon was that clinicians started all over again discovering evidence, which previously had been revealed by basic researchers already.

The advent of ‘translational medicine’, however, represents a fundamentally new aspect where the formerly independent ‘galaxies’ of basic and clinical science find to each other on a fast-track. This involves not only the classical ‘bench-to-bedside’ approach but also increasingly research strategies ‘bedside-to-bench’, which likewise turn out to be extremely fruitful. Additionally, a still much neglected aspect of translational science is the exchange of knowledge between researchers, who focus on different entities that still may share common pathological and curative pathways like for example leukemia and renal cell cancer.

The public audience expects, given the investments made, transformative patient care to be implemented as fast as possible. Only the free exchange of knowledge between researchers from different ‘worlds’ such as engineering, computational biology or chemistry and medicine will help to develop new solutions for common health care problems.

Ideally, ‘translational science’ functions like a neuronal network in it’s every sense that it produces, collects, organizes and presents evidence with all possible scientific and clinical parties involved. The costs of implementing such infrastructures may appear overwhelming. However, currently a floodwave of new and extremely expensive therapies is finding its way into clinical routine, where many of the drugs are effective overall - but sometimes in an unpredictable way in the individual patient. Therefore, sophisticated translational medicine with its potential to develop into personalized medicine will be the only solution for the future, which will be characterized by high expectations in terms of cure rates and economical limitations at the same time.

The symposium »Translations in Urologic Oncology« brings together some of the most eminent people in the field from around the world. It aims to explore today’s frontiers of treatment of tumors that account for approximately twenty-five percent of all malignancies: urological cancers.

Advances in silico as well as imaging, individualized next generation sequencing and tumor profiling, biomarkers, cancer stem cells and immunotherapy as well as current progress in local and systemic therapies will be highlighted. In addition, general aspects of ‘doing science’ such as the more and more urgent pressure to publish and to find the funds that are needed to move the science forward will be discussed.

We cordially welcome you in Heidelberg.

Best regards, on behalf of the organizing committee,

Boris Hadaschik, Sascha Pahernik, Markus Hohenfellner
UniversityHospital Heidelberg
Program Friday 25th January, 2013

Welcome address I
13:00  Markus Hohenfellner, University Hospital Heidelberg

Welcome address II
Guido Adler, University Hospital Heidelberg, Heidelberg

Key note lecture
13:15  From idea to global use
Harald zur Hausen, DKFZ, Heidelberg

Advances in vitro and in silico
Chairs:  Gedse Daugaard, Kopenhagen; Norbert Graf, Homburg; Oliver Hakenberg, Rostock; Christoph Zielinski, Wien
14:00  The 1000 Genomes Project Consortium
Jan Korbel, EMBL, Heidelberg
14:30  What can we learn from the translation of genome analyses in leukemia to common tumors in urology?
Andreas Kulozik, University Hospital Heidelberg
15:00  Genome sequences and next-generation classification of prostate cancer
Holger Sültmann, NCT, Heidelberg
15:30  State of the art – biomarkers
Ronald DePinho, MDACC, Houston
16:15  Discussion, coffee break

Individual profiling of tumors – the future in drug development and multidisciplinary cancer treatment
Chairs:  Markus Elsner, New York; Estrid Hogdall, Kopenhagen; Martina Müller-Schilling, Regensburg
17:10  The preclinical perspective
Stefan Duensing, University Hospital Heidelberg
17:30  The clinical trialist’s perspective
Cora Sternberg, San Camillo and Forlanini Hospitals, Rom
17:50  The NCT perspective on personalized diagnosis and treatment of cancer
Christof von Kalle, NCT, Heidelberg
18:10  Personalized medicine: economic hype or true progress?
Volker Diehl, Cologne University Hospital, Köln
18:30  Round table discussion

Social Event
19:30  Come together at the „Kulturbrauerei“
Program Saturday 26th January, 2013

Imaging advances

Chairs: Abdulla Al Ansari, Doha; Michael Flentje, Würzburg; Axel Haferkamp, Frankfurt; Wolf Wieland, Regensburg

08:30 Urogenital MR-Imaging: the more Tesla the better?
Heinz-Peter Schlemmer, DKFZ, Heidelberg

08:50 At the forefront of radiopharmaceuticals
Uwe Haberkorn, University Hospital Heidelberg

09:10 State of the art – molecular imaging in urological tumors
Hedvig Hricak, MSKCC, New York

09:40 Discussion, coffee break

Perspectives in local and systemic therapy

Chairs: Vito Pansadoro, Rom; Jacob Ramon, Tel Aviv; Jens Rassweiler, Heilbronn; Levent Türkeri, Istanbul; Xu Zhang, Peking

10:30 Navigating towards augmented reality
Dogu Teber, Sascha Pahernik (University Hospital Heidelberg) and Hans-Peter Meinzer (DKFZ, Heidelberg)

10:50 Heavy ion therapy – software guiding hardware for treatment
Jürgen Debus, University Hospital Heidelberg

11:10 Targeted therapy in pediatric urooncology
Hedwig Deubzer, DKFZ, Heidelberg

11:30 State of the art – cancer stem cells and metastasis initiating cells
Andreas Trumpp, DKFZ, Heidelberg

12:00 Round table discussion, lunch break

Applied Translations

Chairs: Maria De Santis, Wien; Michael Droller, New York; Glen Kristiansen, Bonn; Stefan Müller, Bonn; Michael Stöckle, Homburg

13:30 Cancer research from bench to bedside: challenges for urologic oncology
Ottmar Wiestler, DKFZ, Heidelberg

14:00 The future of surgery: lost in translation?
Markus Hohenfellner, Boris Hadaschik, University Hospital Heidelberg

14:30 From phase 2 in clinical routine: the success story of cisplatinum chemotherapy
Peter Albers, Düsseldorf University Hospital

Program Saturday 26th January, 2013

15:00 Translational research – the publisher’s perspective
Markus Eisner, Nature Biotechnology, New York

15:30 Locally advanced and node positive prostate cancer – progress through international co-operation
Fritz Schroeder, Erasmus University and Academic Hospital, Rotterdam

16:00 Discussion, coffee break

Immunotherapy

Chairs: Alessandro Bertaccini, Bologna; Arndt Hartmann, Erlangen; Elke Jäger, Frankfurt; Helmut Klocker, Innsbruck; Bernd Wullich, Erlangen; Martin Zeier, Heidelberg

17:00 Tumor biology and vaccine development
Magnus von Knebel Doeberitz, University Hospital Heidelberg

17:30 Future of cellular immunotherapy
Charles Drake, Johns Hopkins SKCCC, Baltimore

18:00 Modulating the tumor micromilieu
Dirk Jäger, NCT, Heidelberg

18:30 Discussion, farewell
Jürgen Debus
Institution: University Hospital Heidelberg
is Professor of Radiotherapy at the University of Heidelberg and Director of the Department of Radiation Oncology. Since 1997, he is Chair of the German Heavy Ion Radiotherapy Project. His main interests lie in the development of heavy ion therapy and precision radiotherapy to improve patient outcomes.

Stefan Duensing
Institution: University Hospital Heidelberg
is Head of the Section of Molecular Urooncology of the Department of Urology of the University of Heidelberg. His work focuses on genomic instability in cancer and novel ways to detect, treat and prevent prostate and renal cancer.

Markus Hohenfellner
Institution: University Hospital Heidelberg
is Professor of Urology and Director of the Dept. of Urology of the University Hospital Heidelberg. His main activities are uro-oncology including minimally invasive, robotic, ultraradical and reconstructive surgery as well as multimodular interdisciplinary comprehensive cancer therapy. Within the German Cancer Aid Foundation he is specially focused on "novel tools" in oncology and biobanking.

Dirk Jäger
Institution: NCT, Heidelberg
is Head of the Dept. of Medical Oncology and Member of the Board of Directors of the NCT in Heidelberg. His main interest lies in immuno-therapy of cancer using antibody based approaches, T cell based approaches and different strategies of immunomodulation.

Andreas Kulozik
Institution: University Hospital Heidelberg
is Professor of Pediatrics and Director of the Dept. of Pediatric Oncology of the University Hospital Heidelberg. He is interested in personalized treatment approaches in pediatric leukemia and discovered actionable risk markers in precursor T-lymphoblastic leukemia. On a more basic level, he discovered mechanisms of regulated mRNA stability and 3'end mRNA processing.

Heinz-Peter Schlemmer
Institution: DKFZ, Heidelberg
is Head of the Dept. of Radiology at the DKFZ. As both a physicist and physician he is an expert for developing imaging methods for early detection of cancer and characterizing its functional and biologic features. He develops new techniques for ultra-high field MRI and dual-energy CT and PET/CT.

Holger Sültmann
Institution: DKFZ, Heidelberg
is Head of the Cancer Genome Research Unit of the Structural and Functional Genomics Facility at the DKFZ. He is Coordinator and Head of the Integrated Genome Research Project Prostate Cancer as part of the International Cancer Genome Consortium.

Christof von Kalle
Institution: NCT and DKFZ, Heidelberg
is Head of the Dept. of Translational Oncology at the NCT and the DKFZ. He chairs the NCT Board of Directors. He is Chair of the comprehensive cancer center network of the German Cancer Aid. His main research fields are stem cell research, mutation analyses and gene transfer.
Speakers

Guido Adler  
Institution: University Hospital of Cologne  
is Medical Director and Chairman of the Board of the University Hospital of Cologne. He is a leader in the field of Medicine and Gastroenterology and Chairman of the Health Research Board of the German Federal Ministry of Education and Research and a Member of the Austrian Science Board.

Peter Albers  
Institution: Düsseldorf University Hospital  
is Professor and Chairman of the Department of Urology at the University of Düsseldorf, Düsseldorf, Germany. He is an expert in the field of uro-oncology and as such Member of the European Organisation for the Research and Treatment of Cancer (EORTC) GU Group and Chairman of the European Association of Urology (EAU) Testis Cancer Guidelines Group. He is Past Congress President of the German Cancer Congress and was recently elected as Vice Chairman of the German Cancer Society.

Jürgen Debus  
Institution: University Hospital of Heidelberg  
is Professor of Radiotherapy at the University of Heidelberg and Director of the Department of Radiation Oncology. Since 1997, he is Chair of the German Heavy Ion Radiotherapy Project. His main interests lie in the development of heavy ion therapy and precision radiotherapy to improve patient outcomes.

Ronald DePinho  
Institution: MDACC, Houston  
is President of the MD Anderson Cancer Center in Houston, TX, USA. He is an internationally recognized leader in basic and translational cancer research, aging and age-associated degenerative disorders as well as in stem cell research. Dr. DePinho's independent scientific career began at Albert Einstein College of Medicine, where he established the first NCI-supported transgenic and gene targeting facility.

Hedwig Deubzer  
Institution: DKFZ, Heidelberg  
is Group Leader within the Clinical Cooperation Unit Pediatric Oncology of the DKFZ. Her main interest is the investigation of targeted therapies against neuroblastoma. Her research group is working on epigenetic regulations and the master regulators in neuroblastoma biology.

Speakers

Volker Diehl  
Institution: University Hospital of Cologne  
is Director emeritus of the Department of Medicine of the University of Cologne, Germany. He founded the German Hodgkin Study Group, which became and is one of the leading study groups for Hodgkin Disease around the globe, improving the life of thousands of patients. He was the first Director of the NCT in Heidelberg 2004-2005, implementing infrastructure and routines that carry on until today.

Charles Drake  
Institution: Johns Hopkins SKCCC, Baltimore  
is Assistant Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland. He is an expert for immunotherapy and recently presented the clinical usage of a specific inhibitor of T-cells against advanced prostate cancer.

Stefan Duensing  
Institution: University Hospital Heidelberg  
is Head of the Section of Molecular Urooncology of the Department of Urology of the University of Heidelberg. His work focuses on genomic instability in cancer and novel ways to detect, treat and prevent prostate and renal cancer.

Markus Elsner  
Institution: Nature Biotechnology, New York  
is an Associate Editor of Nature Biotechnology. With a 2011 impact factor of 23.268 Nature Biotechnology places first among the primary research journals in the field of biotechnology. He did his graduate work at EMBL in Heidelberg, and the University of Gothenburg, Sweden, where he worked on characterizing protein dynamics in living cells. In his postdoctoral studies at the NIH he investigated the mechanisms of lipid and protein sorting during membrane transport events.

Uwe Haberkorn  
Institution: University Hospital Heidelberg  
is Head of the Dept. of Nuclear Medicine at the University Heidelberg and Head of the Clinical Cooperation Unit Nuclear Medicine at the DKFZ. His science focuses on PET-imaging, identification of new peptides with high affinity for tumor disease and the establishment of new endoradiotherapy approaches based on peptides and antibodies.
Andreas Kulozik  
**Institution:** University Hospital Heidelberg  
is Professor of Pediatrics and Director of the Dept. of Pediatric Oncology of the University Hospital Heidelberg. He is interested in personalized treatment approaches in pediatric leukemia and discovered actionable risk markers in precursor T-lymphoblastic leukemia. On a more basic level, he discovered mechanisms of regulated mRNA stability and 3'end mRNA processing.

Hans-Peter Meinzer  
**Institution:** NCT, Heidelberg  
is Head of the Division of Medical and Biological Informatics at the DKFZ. His research aims at improving diagnostic methods and treatment planning based on CT, MRI and ultrasound. Preoperative and intraoperative imaging as well as surgical navigation are his major scientific topics.

Sascha Pahernik  
**Institution:** University Hospital Heidelberg  
is Associate Professor at the Dept. of Urology of the University Hospital Heidelberg. His research focuses on surgical and medical treatment of renal cell carcinoma and the clinical development of focal ablative therapies such as HIFU for prostate cancer. He is member of the scientific council of the Else Kröner Fresenius Stiftung.

Heinz-Peter Schlemmer  
**Institution:** DKFZ, Heidelberg  
is Head of the Dept. of Radiology at the DKFZ. As both a physicist and physician he is an expert for developing imaging methods for early detection of cancer and characterizing its functional and biologic features. He develops new techniques for ultra-high field MRI and dual-energy CT and PET/CT.

Fritz Schröder  
**Institution:** Erasmus University and Academic Hospital, Rotterdam  
is past Chairman of the Department of Urology, Erasmus MC, the Netherlands. He is a clinical expert for prostate cancer and the international coordinator of the ERSPC, a prospective study that randomized 162,000 men across Europe to prove that PSA screening can indeed reduce the mortality of prostate cancer.

**Speakers**

**Boris Hadaschik**  
**Institution:** University Hospital Heidelberg  
is Associate Professor at the Dept. of Urology, University Hospital Heidelberg. He obtained the Maximilian-Nitze-Prize for his work regarding novel intravesical agents and an orthotopic mouse model for bladder cancer. His current research focuses on prostate cancer including the development of image-guided prostate biopsy strategies and their implementation in international study groups as well as clinical trials for castration-resistant disease.

**Markus Hohenfellner**  
**Institution:** University Hospital Heidelberg  
is Professor of Urology and Director of the Dept. of Urology of the University Hospital Heidelberg. His main activities are uro-oncology including minimally invasive, robotic, ultraradical and reconstructive surgery as well as multimodal interdisciplinary comprehensive cancer therapy. Within the German Cancer Aid Foundation he is specially focused on »novel tools« in oncology and biobanking.

**Hedvig Hricak**  
**Institution:** MSKCC, New York  
is Chairman of the Dept. of Radiology at the Memorial Sloan-Kettering Cancer Center, New York. She is one of the most renowned American radiologists. She is Professor of Radiology at the Weill Medical College of Cornell University and investigates imaging methods for cancer detection and staging.

**Dirk Jäger**  
**Institution:** NCT, Heidelberg  
is Head of the Dept. of Medical Oncology and Member of the Board of Directors of the NCT in Heidelberg. His main interest lies in immunotherapy of cancer using antibody based approaches, T cell based approaches and different strategies of immunomodulation.

**Jan Korbel**  
**Institution:** EMBL Heidelberg  
is Group Leader at the EMBL. His lab studies the impact of genetic variants (SVs). In developing next-generation cancer genomics they decipher the impact of SVs in diseases. They discovered chromothripsis as an event, in which SVs are crucial for the development of childhood medulloblastoma.

**Andreas Kulozik**  
**Institution:** University Hospital Heidelberg  
is Professor of Pediatrics and Director of the Dept. of Pediatric Oncology of the University Hospital Heidelberg. He is interested in personalized treatment approaches in pediatric leukemia and discovered actionable risk markers in precursor T-lymphoblastic leukemia. On a more basic level, he discovered mechanisms of regulated mRNA stability and 3'end mRNA processing.

**Hans-Peter Meinzer**  
**Institution:** NCT, Heidelberg  
is Head of the Division of Medical and Biological Informatics at the DKFZ. His research aims at improving diagnostic methods and treatment planning based on CT, MRI and ultrasound. Preoperative and intraoperative imaging as well as surgical navigation are his major scientific topics.

**Sascha Pahernik**  
**Institution:** University Hospital Heidelberg  
is Associate Professor at the Dept. of Urology of the University Hospital Heidelberg. His research focuses on surgical and medical treatment of renal cell carcinoma and the clinical development of focal ablative therapies such as HIFU for prostate cancer. He is member of the scientific council of the Else Kröner Fresenius Stiftung.

**Heinz-Peter Schlemmer**  
**Institution:** DKFZ, Heidelberg  
is Head of the Dept. of Radiology at the DKFZ. As both a physicist and physician he is an expert for developing imaging methods for early detection of cancer and characterizing its functional and biologic features. He develops new techniques for ultra-high field MRI and dual-energy CT and PET/CT.

**Fritz Schröder**  
**Institution:** Erasmus University and Academic Hospital, Rotterdam  
is past Chairman of the Department of Urology, Erasmus MC, the Netherlands. He is a clinical expert for prostate cancer and the international coordinator of the ERSPC, a prospective study that randomized 162,000 men across Europe to prove that PSA screening can indeed reduce the mortality of prostate cancer.
Magnus von Knebel Doeberitz
Institution: DKFZ, Heidelberg
is Head of the Clinical Cooperation Unit Applied Cancer Biology at the DKFZ. Their main interests lie in the detection of oncogenic viruses and in detection of early cancer stages as well as the biology of unstable microsatellites in neoplasia. He founded the biotech company MTM laboratories.

Otmar Wiestler
Institution: DKFZ, Heidelberg
is Chairman of the Management Board and Scientific Director of the DKFZ, thereby leading the largest biomedical research institute in Germany into the 21st century. At the DKFZ, more than 2,500 employees in over 70 divisions and research groups are investigating the basic mechanisms of cancer.

Harald zur Hausen
Institution: DKFZ, Heidelberg
is Nobel Prize laureate in Medicine for his outstanding scientific contributions and identification of papillomaviruses in cervical cancers that led to the development of a vaccine. He was Chairman of the DKFZ from 1983 - 2003. He actively took part in the establishment of the National Center of Tumor Diseases in Heidelberg and was President of the German Cancer Aid Foundation in 2010/11.

Cora Sternberg
Institution: San Camillo and Forlanini Hospitals, Rom
is Head of the Dept. of Medical Oncology at the San Camillo and Forlanini Hospitals in Rome and an internationally recognized leader in uro-oncology. She pioneered the MVAC treatment regime against bladder cancer during her time at the MSKCC in New York. Today she is involved in the work of the EORTC, especially in the Genito-Urinary Cancers Group and greatly contributes to the development of clinical trials.

Holger Sültmann
Institution: DKFZ, Heidelberg
is Head of the Cancer Genome Research Unit of the Structural and Functional Genomics Facility at the DKFZ. He is Coordinator and Head of the Integrated Genome Research Project Prostate Cancer as part of the International Cancer Genome Consortium.

Dogu Teber
Institution: University Hospital Heidelberg
is Senior Physician at the Dept. of Urology University Hospital Heidelberg. His special affiliation is in the field of minimally invasive urological surgery. His main research interests lie in intraoperative navigation and in new technologies in urological imaging.

Andreas Trumpp
Institution: DKFZ, Heidelberg
is Head of the Department Stem Cells and Cancer at the DKFZ and Managing Director of HI-STEM gGmbH. HI-STEM elucidates the molecular and cellular basis for normal and malignant stem cell function and furthermore develops strategies to detect and target cancer and metastasis stem cells.

Christof von Kalle
Institution: NCT and DKFZ, Heidelberg
is Head of the Dept. of Translational Oncology at the NCT and the DKFZ. He chairs the NCT Board of Directors. He is Chair of the comprehensive cancer center network of the German Cancer Aid. His main research fields are stem cell research, mutation analyses and gene transfer.
Transparenz


Dieser Verpflichtung kommen wir nach und informieren Sie über die Höhe des Sponsorings der beteiligten Firmen:

- Baxter Deutschland GmbH 3.000,00 Euro
- Bayer Vital GmbH 5.000,00 Euro
- Coloplast GmbH 1.000,00 Euro
- GlaxoSmithKline GmbH & Co. KG 8.000,00 Euro
- Jansen-Cilag GmbH 10.000,00 Euro
- Johnson & Johnson Medical GmbH (ETHICON Biosurgery) 2.000,00 Euro
- MedCom GmbH und Watson Medical 4.000,00 Euro
- Novartis Pharma GmbH 8.000,00 Euro
- Pfizer Pharma GmbH 5.000,00 Euro
- Roche Pharma AG 8.000,00 Euro
- Siemens AG 4.000,00 Euro
- Takeda Pharma Vertrieb GmbH & Co. KG 10.000,00 Euro
European Foundation for Urology
Heidelberg

The medicine of the 21st century is increasingly influenced by socio-political, and particularly economic circumstances, which are leading to an integration of curing and relieving illnesses into the algorithms of market economy financial systems. This development is being intensified not only by the cost explosion in developing and applying new diagnostic and therapeutic techniques, but also by the demographic change of our population structure. Without being expressed this is leading to a questioning of the ethics that have given primacy to the wellbeing of the sick in our collective consciousness for centuries. The young and healthy funders of our society in particular are, not least legitimized by the media influence of political parties, increasingly prepared to accept these perspectives of the “financial feasibility” of health.

The European Foundation for Urology is making a contribution to the retention of “salus aegroti suprema lex” by the voluntary solidarity of its donors towards ill people whose medical treatment would not otherwise be financeable. This target is achieved firstly through direct, earmarked support for patients and secondly, through the individual, selective training of doctors from other national and international institutions. The discipline of urology is particularly suitable for such a project for many reasons. Firstly urology is confronted with illnesses of patients from all age groups, from new-borns to old people, who can very frequently be completely cured by the correct therapy. Examples that can be named include congenital deformities, the consequences of accidents, tumours and organ disorders. Secondly, the discipline of urology is well-organized, manageable and professional, the expertise of which relates not least to intensive national and international collegiality and exchanges of academic experiences.

More on this issue under: www.efu-heidelberg.de
General Information

Principal organiser
Boris Hadaschik
Sascha Pahernik

CME
Accredited 14 points, category A, by the German LÄK Baden-Württemberg. Granted 9 European CME credits by the EACCME

Scientific Organisation
Timur Kuru, Thomas Höfner
Department of Urology, University Hospital Heidelberg

Congress Organisation
wikonect GmbH | Hagenauer Straße 53 | D-65203 Wiesbaden
Tel.: +49 (0)611 - 20 48 09 21 | Fax: +49 (0)611 - 20 48 09 10
info@wikonect.de | www.wikonect.de

Congress Host
med publico GmbH | Hagenauer Straße 53 | D-65203 Wiesbaden

Location
Communication Center, DKFZ | Im Neuenheimer Feld 280 | 69120 Heidelberg | www.dkfz.de

Patrons of Translations in Urologic Oncology

The congress is supported by the European Foundation for Urology